<DOC>
	<DOCNO>NCT00841295</DOCNO>
	<brief_summary>Background : Carnitine essential cofactor various enzyme activity human metabolism , especially mitochondrial carnitine shuttle transfer long-chain fatty acid acylcarnitine ester across inner mitochondrial membrane Beta-oxidation energy production . Intracellular carnitine deficiency induces impairment long-chain fatty acid oxidation . In human , approximately 75 % carnitine come diet 25 % endogenous liver synthesis . In neonatal period , specifically premature , liver synthesis capacity reduce immaturity biosynthetic pathway , carnitine level relate exogenous source . Traditionally , carnitine add parenteral nutrition . Indeed , without enteral feed carnitine supplementation parenteral nutrition , preterm infant ' plasma carnitine level fall first week life , particularly subject require prolong exclusive parenteral nutrition . The potential deleterious role carnitine deficiency clearly demonstrate infant . However , patient primary carnitine deficiency , genetic defect carnitine transport induce severe carnitine deficiency , commonly develop liver symptom ( encompass visceral steatosis , hyperammonemia recurrent hypoketotic hypoglycemia ) and/or cardiomyopathy myopathy . In latter patient , carnitine supplementation improve symptom . Hypothesis : Carnitine deficiency premature low birth weight infant may one factor involve liver disease frequently associate prolonged parenteral nutrition , may deleterious effect cardiac muscle metabolism function . Aims : To demonstrate beneficial effect parenteral carnitine supplementation premature neonates liver , heart muscle metabolism function . Study Type : Multicentric prospective randomise study Subjects : Premature low birth weight neonate , define gestational age minor equal 28 week and/or birth weight minor equal 1000 gram , 80 subject enrol 2.5 year Interventions : Arm 1 ( experimental ) : parenteral carnitine supplementation ( 9 ± 1 mg/kg/d ) , day 4 , enteral nutrition provide sufficient carnitine source ; Arm 2 ( Placebo comparator ) : parenteral supplementation equivalent volume sterile water .</brief_summary>
	<brief_title>Effects Parenteral L-carnitine Supplementation Premature Neonates</brief_title>
	<detailed_description>Background : Carnitine essential cofactor various enzyme activity human metabolism , especially mitochondrial carnitine shuttle transfer long-chain fatty acid acylcarnitine ester across inner mitochondrial membrane Beta-oxidation energy production . Intracellular carnitine deficiency induces impairment long-chain fatty acid oxidation . In human , approximately 75 % carnitine come diet 25 % endogenous liver synthesis . In neonatal period , specifically premature , liver synthesis capacity reduce immaturity biosynthetic pathway , carnitine level relate exogenous source . Traditionally , carnitine add parenteral nutrition . Indeed , without enteral feed carnitine supplementation parenteral nutrition , preterm infant ' plasma carnitine level fall first week life , particularly subject require prolong exclusive parenteral nutrition . The potential deleterious role carnitine deficiency clearly demonstrate infant . However , patient primary carnitine deficiency , genetic defect carnitine transport induce severe carnitine deficiency , commonly develop liver symptom ( encompass visceral steatosis , hyperammonemia recurrent hypoketotic hypoglycemia ) and/or cardiomyopathy myopathy . In latter patient , carnitine supplementation improve symptom . Hypothesis : Carnitine deficiency premature low birth weight infant may one factor involve liver disease frequently associate prolonged parenteral nutrition , may deleterious effect cardiac muscle metabolism function . Aims : To demonstrate beneficial effect parenteral carnitine supplementation premature neonates liver , heart muscle metabolism function . Study Type : Multicentric prospective randomise study Subjects : Premature low birth weight neonate , define gestational age minor equal 28 week and/or birth weight minor equal 1000 gram , 80 subject enrol 2.5 year Interventions : Arm 1 ( experimental ) : parenteral carnitine supplementation ( 9 ± 1 mg/kg/d ) , day 4 , enteral nutrition provide sufficient carnitine source ; Arm 2 ( Placebo comparator ) : parenteral supplementation equivalent volume sterile water . Primary Outcome : Plasma Gamma Glutamyl Transferase level 21 day parenteral supplementation . Secondary Outcomes : Short- ( parenteral supplementation ) long- ( 3 5 month age ) term outcome : 1 ) Liver function ( level ammonemia , hyaluronic acid , bilirubin , prothrombin time test , ursodeoxycholic acid therapy ) , 2 ) cardiac function ( echocardiography , EKG ) , 3 ) muscle integrity ( CK level ) , 4 ) neurological injury ( brain ultrasound MRI ) , 5 ) respiratory immaturity , 6 ) acylcarnitine profile fatty acid derivative . Expected Findings : Systematic parenteral carnitine supplementation prevent systemic carnitine deficiency , improve liver dysfunction ( decreased duration severity liver disease ) associate prolonged parenteral nutrition , improve cardiac muscle function , prevent cerebral injury premature infant low birth weight .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<criteria>Premature newborn admit Intensive Care Unit , Gestational age minor equal 28 week 6 day , Needing prolonged parenteral nutrition central intravenous catheter , Parenteral nutrition start 6 day life , Both parent ( legal tutor ) give write informed consent child , Patient affiliate `` Sécurité Sociale '' parent . Severe associated disorder , probable shortterm death , Identified genetic disease , Polymalformative syndrome , severe malformation ( heart , brain , others… ) , Inborn error metabolism , Probable transfer subject 25 day life another hospital collaborate study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>28 Weeks</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>